FILE:BIIB/BIIB-8K-20100112160606.txt.gz
EVENTS:	Results of Operations and Financial Condition
TEXT:
ITEM: Results of Operations and Financial Condition
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (General Instruction A.2. below):
see
 
 
 
     Biogen Idec Inc. announced today that sales of TYSABRI (natalizumab) during 2009 were approximately $1,059.2 million, comprised of approximately $508.5 million of sales in the United States and approximately $550.7 million of sales in the rest of the world.
 
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 12, 2010


